99902-96-2Relevant articles and documents
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: Identification of candidates for clinical development
Letavic, Michael A.,Aluisio, Leah,Atack, John R.,Bonaventure, Pascal,Carruthers, Nicholas I.,Dugovic, Christine,Everson, Anita,Feinstein, Mark A.,Fraser, Ian C.,Hoey, Kenway,Jiang, Xiaohui,Keith, John M.,Koudriakova, Tatiana,Leung, Perry,Lord, Brian,Lovenberg, Timothy W.,Ly, Kiev S.,Morton, Kirsten L.,Timothy Motley,Nepomuceno, Diane,Rizzolio, Michele,Rynberg, Raymond,Sepassi, Kia,Shelton, Jonathan
scheme or table, p. 4210 - 4214 (2010/09/04)
The pre-clinical characterization of novel aryloxypyridine amides that are histamine H3 receptor antagonists is described. These compounds are high affinity histamine H3 ligands that penetrate the CNS and occupy the histamine H3 receptor in rat brain. Several compounds were extensively profiled pre-clinically leading to the identification of two compounds suitable for nomination as development candidates.
Antipicornavirus activity of substituted phenoxybenzenes and phenoxypyridines
Markley,Tong,Dulworth,Steward,Goralski,Johnston,Wood,Vinogradoff,Bargar
, p. 427 - 433 (2007/10/02)
Phenoxybenzenes and phenoxypyridines were prepared and tested for the effect of substituents on antipicornavirus activity. The most active compound, 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (8), demonstrated broad-spectrum antipicornavirus activity. Co